| abstract |
PROBLEM TO BE SOLVED: To provide a cancer-specific trans-splicing ribozyme and its use. The present invention relates to a cancer-specific trans-splicing ribozyme and its use. The trans-splicing ribozyme according to the present invention does not act on normal tissues and is specifically expressed in cancer tissues, so that it is highly safe and has excellent expression efficiency at the post-transcriptional level, and is therefore usefully used in the treatment of cancer. obtain. Specifically, the recombinant vector of the present invention has a CMV promotor, SD / SA and WPRE, so that the expression efficiency of ribozyme is high, and miR-122T is possessed and the activity can be regulated by miR-122. , Excellent safety. Therefore, among liver cancers caused by HCV, miR-122 can be effectively used in the treatment of all liver cancers except for some liver cancers in which the expression level of miR-122 is higher in cancer tissues than in normal tissues. for the treatment of substantially not expressed other cancer tumors may be effectively used. [Selection diagram] Fig. 1 |